The immunosuppressive drug methotrexate (MTX) can be linked to an elevated risk of three types of skin cancer, a new study by University of Gothenburg researchers shows.
The safety profile and the actual known adverse effects of COVID-19 vaccines in at-risk and healthy individuals
Researchers discussed the safety of COVID-19 vaccines in healthy people and patients with autoimmunity or cardiac issues.
Messenger RNAs (mRNAs) contain chemical marks that are critical for antiviral defense in cells, according to a new study from researchers at Weill Cornell Medicine.
Researchers examined the associations between coronavirus disease 2019 (COVID-19) and incident autoimmune diseases.
A research team, led by Professor Sung Ho Park in the Department of Biological Sciences at UNIST announced the results of a study on osteoblasts that damage joint bones in patients with rheumatoid arthritis.
Scientists at University of California San Diego School of Medicine have developed an artificial intelligence (AI)-based strategy for discovering high-affinity antibody drugs.
A potential treatment for moderate-to-severe rheumatoid arthritis, sirukumab, is under consideration by the U.S. Food and Drug Administration for approval, with the application supported by results from five Phase 3 clinical trials. Johnson & Johnson (J&J) one of the companies developing sirukumab — through its subsidiary Janssen, working with GlaxoSmithKline — said in a recent business review statement that it anticipates approval […]
Group-based quality improvement sessions, based on the recommended “treat to target” (TTT) approach, can help rheumatologists improve the quality of their care for rheumatoid arthritis (RA) patients, a recent study suggests. Results of the study, “Implementation of Treat to Target in Rheumatoid Arthritis through a Learning Collaborative: Results of the TRACTION Randomized Controlled Trial,” were […]
Kevzara (sarilumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with moderate to severely active rheumatoid arthritis (RA) who have not responded to or are intolerant to disease-modifying antirheumatic drugs (DMARDs) such as methotrexate (MTX). The wholesale price of the new treatment is about 30 percent less […]
Can-Fite BioPharma has filed a clinical trial application (CTA) with Health Canada for piclidenoson (CF101) as a treatment for rheumatoid arthritis (RA). Piclidenoson is an orally bioavailable drug with a favorable therapeutic index that is under development for the treatment of autoimmune inflammatory diseases like RA and psoriasis. It’s a new, first-in-class A3 adenosine receptor agonist (A3AR). […]